These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 3181234)

  • 1. Mouse bladder carcinoma as a model to study immune manipulations in man.
    Hellström KE; Hellström I
    Eur Urol; 1988; 14 Suppl 1():17-8. PubMed ID: 3181234
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunotherapy: The development of immunotherapy in urothelial bladder cancer.
    Powles T
    Nat Rev Clin Oncol; 2015 Apr; 12(4):193-4. PubMed ID: 25781573
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunotherapy of xenografted human bladder cancer in nude mice using monoclonal antibody.
    Yu DS; Yeh MY; Chang SY; Ma CP; Han SH
    Eur Urol; 1987; 13(3):198-202. PubMed ID: 3301365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunotherapy of xenografted human bladder cancer using monoclonal antibody against blood group A-related antigen.
    Yeh MY; Yu DS; Chang SY; Ma CP; Han SH
    Eur Urol; 1988; 14(5):386-90. PubMed ID: 3169082
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy of bladder tumors.
    Herr HW
    Uremia Invest; 1984-1985; 8(3-4):257-61. PubMed ID: 6400156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [BCG-instillation therapy in superficial bladder tumor--host immune response elicited by local application of BCG].
    Hayakawa M; Hatano T; Saito S; Miyazato T; Nakayama M; Igarashi M; Saita H
    Nihon Hinyokika Gakkai Zasshi; 1987 Nov; 78(11):1972-81. PubMed ID: 3502480
    [No Abstract]   [Full Text] [Related]  

  • 7. Keyhole-limpet haemacyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma.
    Lamm DL; Reyna JA; Reichert DF
    Urol Res; 1981; 9(5):227-30. PubMed ID: 7303346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Trials of immunotherapy in tumors of the urinary tract].
    Corrado F; Pizza G
    Arch Esp Urol; 1984 Dec; 37 Suppl 2():659-66. PubMed ID: 6336141
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunohistochemical markers defined by monoclonal antibodies and response to bacillus Calmette-Guérin endovesical immunotherapy for superficial bladder tumors.
    Flam TA; Chopin DK; Leleu C; Abbou CC; Steg A; Deslignères S; Boccon-Gibod L
    Eur Urol; 1990; 17(4):338-42. PubMed ID: 1694766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive immunotherapy and radiotherapy in the treatment of urinary bladder cancer.
    Symes MO; Eckert H; Feneley RC; Lai T; Mitchell JP; Roberts JB; Tribe CR
    Br J Urol; 1978 Aug; 50(5):328-31. PubMed ID: 753485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cytokine therapy of superficial bladder carcinoma. Mechanisms of action and results of therapy].
    Otto T; Kälble T
    Urologe A; 1994 Nov; 33(6):540-6. PubMed ID: 7817454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer.
    Lamm DL
    Nihon Hinyokika Gakkai Zasshi; 1995 Jan; 86(1):9-10. PubMed ID: 7897925
    [No Abstract]   [Full Text] [Related]  

  • 13. Immunotherapy for the treatment of superficial and infiltrative bladder carcinoma.
    Cockett AT; Merguerian PA; di Sant'Agnese PA; Wheeless LL
    Prog Clin Biol Res; 1989; 303():455-62. PubMed ID: 2675003
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro produced human antibodies in the treatment of superficial bladder cancer.
    Corrado F; Pizza G; Casanova S; De Vinci C; Fini M; Severini G; Menniti D; Corrado G
    J Exp Pathol; 1987; 3(4):347-58. PubMed ID: 3454800
    [No Abstract]   [Full Text] [Related]  

  • 15. Editorial comment on: celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma.
    Brandau S
    Eur Urol; 2008 Sep; 54(3):629-30. PubMed ID: 18222602
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
    Lamm DL; DeHaven JI; Riggs DR; Ebert RF
    J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of superficial transitional cell carcinoma of the bladder.
    Fleischmann J; Goldberg G
    Semin Urol; 1993 Nov; 11(4):193-204. PubMed ID: 8290825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutated ras p21 as a target for cancer therapy in mouse transitional cell carcinoma.
    Luo Y; Chen X; Han R; Chorev M; Dewolf WC; O'Donnell MA
    J Urol; 1999 Oct; 162(4):1519-26. PubMed ID: 10492248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Not Available].
    Thibault C
    Bull Cancer; 2018 Dec; 105 Suppl 1():S43-S49. PubMed ID: 30595198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiproliferative effect of IL-6 on transitional cell carcinoma of the bladder. Insight into mechanisms of bacillus Calmette-Guerin immunotherapy.
    Alexandroff AB; Black J; Esuvaranathan K; James K
    Biochem Soc Trans; 1997 May; 25(2):270S. PubMed ID: 9191314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.